Welcome to our dedicated page for Talphera news (Ticker: tlph), a resource for investors and traders seeking the latest updates and insights on Talphera stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Talphera's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Talphera's position in the market.
Talphera Inc. (Nasdaq: TLPH), a specialty pharmaceutical company, has announced it will release its second quarter 2024 financial results after market close on Wednesday, August 14, 2024. The company will host a live webcast and conference call at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide a business update.
Investors can access the webcast through the company's website or join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using the conference ID 28132. The webcast will include a slide presentation, and a replay will be available on Talphera's website for 90 days following the event.
Talphera, a specialty pharmaceutical company, has announced the grant of inducement awards to Dr. Shakil Aslam, the newly appointed Chief Development Officer. These awards, approved by Talphera's Board of Directors on May 20, 2024, include a non-statutory stock option for 185,000 shares and a restricted stock unit award for 32,000 shares. The stock options have an exercise price of $1.08 per share and will vest 25% on May 20, 2025, with the remaining shares vesting monthly over three years. The restricted stock units will vest in equal installments over three years, starting May 20, 2025. These awards were granted under Nasdaq Listing Rule 5635(c)(4) but are governed by Talphera's 2020 Equity Incentive Plan.
Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, has announced its participation in the A.G.P. Virtual Healthcare Conference on May 21, 2024, at 10:40 a.m. ET. The management will engage in a fireside chat format to discuss the company's innovative therapies developed for medically supervised settings. This session aims to provide insights into Talphera's business strategies and future plans. Attendees can join the webcast through a provided link.
Talphera (Nasdaq: TLPH) announced its Q1 2024 financial results and provided a corporate update. The company reported cash and investments of $18.6 million as of March 31, 2024. Combined R&D and SG&A expenses were $4.2 million, down from $5.3 million in Q1 2023, due to reduced headcount from divesting DSUVIA. Net loss from continuing operations was $4.0 million, compared to net income of $0.1 million in Q1 2023, due to changes in the fair value of the company's warrant liability. The NEPHRO CRRT study is set to enroll its first patients in Q2 2024. Dr. Shakil Aslam joins as Chief Development Officer on May 20, 2024.
Talphera, Inc. (NASDAQ: TLPH) will release its first quarter 2024 financial results on May 14, 2024, followed by a live webcast and conference call to discuss the results and provide a business update. The webcast can be accessed on the company's website, and the conference call details are provided for investors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.